Renaissance Technologies - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$70
-11.4%
59,700
+6.8%
0.00%
Q2 2023$79
-99.8%
55,900
+143.0%
0.00%
Q4 2020$40,000
-90.7%
23,000
-95.0%
0.00%
Q3 2020$432,000
+0.9%
460,806
-6.3%
0.00%
Q2 2020$428,000
+92.8%
491,700
+83.2%
0.00%
Q1 2020$222,000268,4000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$83,313,0005.12%
Defender Capital, LLC. 4,997,870$12,245,0003.92%
Raffles Associates 543,590$1,332,0001.28%
Prescott General Partners LLC 1,851,851$4,537,0000.16%
DCF Advisers, LLC 85,000$208,0000.08%
Long Focus Capital Management, LLC 215,000$527,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$110,0000.06%
DAFNA Capital Management LLC 80,000$196,0000.05%
Strategic Wealth Investment Group, LLC 65,069$159,0000.04%
Fort Sheridan Advisors LLC 52,931$130,0000.04%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders